Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473952 | 0.75 | FFAR1 (0.48) | TACR1FFAR1FFAR4 | |
| SCHEMBL6481974 | 0.73 | FFAR1 (0.47) | TACR1FFAR1FFAR4 | |
| SCHEMBL6001481 | 0.72 | PTPN1 (0.61) | PTPN1PTPN11CA2PPARAPPARG | |
| SCHEMBL6486507 | 0.71 | MCL1 (0.45) | — | |
| SCHEMBL6475120 | 0.69 | CYSLTR2 (0.47) | CA2SMN1; SMN2 | |
| SCHEMBL6475739 | 0.69 | PTPN1 (0.48) | PTPN1FFAR1CA2 | |
| SCHEMBL6474127 | 0.68 | CYSLTR2 (0.43) | PPARAMAPK1SMN1; SMN2 | |
| SCHEMBL216185 | 0.68 | PTPN1 (0.62) | PTPN1PTPN11CA2MAPK1SMN1; SMN2 | |
| SCHEMBL6479679 | 0.67 | KDM1A (0.42) | CA2PPARAPPARG | |
| SCHEMBL6482194 | 0.67 | KDM1A (0.43) | CA2PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | TACR1 1541/4885PTPN1 54/4885FFAR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.